Cover Image
市場調查報告書

異染性腦白質退化症 (MLD) :開發中產品分析

Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 362366
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
異染性腦白質退化症 (MLD) :開發中產品分析 Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 35 Pages
簡介

本報告提供異染性腦白質退化症 (MLD) 治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

異染性腦白質退化症 (MLD)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

異染性腦白質退化症 (MLD):企業開發中的治療藥

異染性腦白質退化症 (MLD):大學/機關研究中的治療藥

異染性腦白質退化症 (MLD):開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

異染性腦白質退化症 (MLD):企業開發中的產品

異染性腦白質退化症 (MLD):大學/機關研究中的產品

異染性腦白質退化症 (MLD的)治療藥的開發企業

  • ArmaGen Inc.
  • GlaxoSmithKline Plc
  • RegenxBio Inc.
  • Shire Plc

異染性腦白質退化症 (MLD):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

異染性腦白質退化症 (MLD):最近的開發平台趨勢

異染性腦白質退化症 (MLD):暫停中的計劃

異染性腦白質退化症 (MLD):開發中止的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9409IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape.

Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms especially of the neck, spine, arms, and legs. Treatment for metachromatic leukodystrophy is symptomatic and supportive.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (MLD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metachromatic Leukodystrophy (MLD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Metachromatic Leukodystrophy (MLD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metachromatic Leukodystrophy (MLD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metachromatic Leukodystrophy (MLD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metachromatic Leukodystrophy (MLD) (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metachromatic Leukodystrophy (MLD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metachromatic Leukodystrophy (MLD) - Overview
    • Metachromatic Leukodystrophy (MLD) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Metachromatic Leukodystrophy (MLD) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Metachromatic Leukodystrophy (MLD) - Companies Involved in Therapeutics Development
    • ArmaGen Inc
    • GlaxoSmithKline Plc
    • Recursion Pharmaceuticals LLC
    • RegenxBio Inc
    • Shire Plc
  • Metachromatic Leukodystrophy (MLD) - Drug Profiles
    • AGT-183 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DUOC-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2696274 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGTA-456 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-611 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Metachromatic leukodystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metachromatic Leukodystrophy (MLD) - Dormant Projects
  • Metachromatic Leukodystrophy (MLD) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Metachromatic Leukodystrophy (MLD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Metachromatic Leukodystrophy (MLD) - Pipeline by ArmaGen Inc, H1 2017
  • Metachromatic Leukodystrophy (MLD) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Metachromatic Leukodystrophy (MLD) - Pipeline by Recursion Pharmaceuticals LLC, H1 2017
  • Metachromatic Leukodystrophy (MLD) - Pipeline by RegenxBio Inc, H1 2017
  • Metachromatic Leukodystrophy (MLD) - Pipeline by Shire Plc, H1 2017
  • Metachromatic Leukodystrophy (MLD) - Dormant Projects, H1 2017
  • Metachromatic Leukodystrophy (MLD) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Metachromatic Leukodystrophy (MLD), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top